Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.49 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.46 |
| ▸ | PTGFR | P43088 | 2/20 | 0.46 |
| ▸ | PTGIR | P43119 | 2/20 | 0.46 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.46 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.46 |
| ▸ | ITGAL | P20701 | 1/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.46 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.46 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6822168 | 1.00 | CA1 (0.50) | CA1CA2NFKB1CA4PTGER3 | |
| SCHEMBL6821922 | 0.86 | HDAC1 (0.45) | NFKB1MAPTLMNAKDM4ENPC1 | |
| SCHEMBL6821923 | 0.86 | HDAC1 (0.45) | NFKB1MAPTLMNAKDM4ENPC1 | |
| SCHEMBL30560915 | 0.84 | HDAC1 (0.44) | NFKB1MAPTLMNAKDM4ENPC1 | |
| SCHEMBL1339826 | 0.81 | PTGS2 (0.55) | CA1CA2NFKB1CA4PTGER3 | |
| SCHEMBL1124437 | 0.81 | PTGS2 (0.55) | CA1CA2NFKB1CA4PTGER3 | |
| SCHEMBL1339824 | 0.81 | PTGS2 (0.55) | CA1CA2NFKB1CA4PTGER3 | |
| SCHEMBL1124438 | 0.81 | PTGS2 (0.55) | CA1CA2NFKB1CA4PTGER3 | |
| SCHEMBL9005515 | 0.81 | HDAC1 (0.41) | NFKB1MAPTLMNAKDM4ENPC1 | |
| SCHEMBL9005509 | 0.81 | HDAC1 (0.41) | NFKB1MAPTLMNAKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50594-E1 | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-09-23 | — | — | US | disclosed |
| CN-119569739-A | Compounds and derivatives thereof as MDM2-P53 inhibitors | 勃林格殷格翰国际有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119569740-A | Compounds and derivatives thereof as MDM2-P53 inhibitors | 勃林格殷格翰国际有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119569741-A | Compounds and derivatives thereof as MDM2-P53 inhibitors | 勃林格殷格翰国际有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-116768792-B | Cinnamamide-hydroxypyridone derivative, and preparation method and application thereof | 浙江工业大学 | 2024-10-18 | — | — | CN | disclosed |
| CN-116768792-A | Cinnamamide-hydroxypyridone derivative, and preparation method and application thereof | 浙江工业大学 | 2023-09-19 | — | — | CN | disclosed |
| EP-2867226-B1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2018-11-14 | — | — | EP | disclosed |
| US-9815819-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2017-11-14 | — | — | US | disclosed |
| US-20150141455-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-05-21 | — | — | US | disclosed |
| EP-2867226-A2 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | Novartis AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| WO-2014002051-A2 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-01-03 | — | — | WO | disclosed |
| WO-2004046122-A2 | BENZOXAZOLE, BENZTHIAZOLE AND BENZIMIDAZOLE ACID DERIVATIVES AND THEIR USE AS HEPARANASE INHIBITORS | OXFORD GLYCOSCIENCES (UK) LTD (GB) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141455-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | C5, C3AR1, C9 | CA1 4702/4885CA2 4148/4885NFKB1 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.